Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Novo Nordisk 12.087, AstraZeneca 15.384.
Novo Nordisk vs AstraZeneca: Revenue Comparison
Novo Nordisk (NVO) and AstraZeneca (AZN) are peers in GLP-1. Novo Nordisk reported revenue of $12.1B as of Q2 2026, compared with $15.4B for AstraZeneca. AstraZeneca leads on revenue.
Novo Nordisk's gross margin is 78.2% versus 83.6% for AstraZeneca. Novo Nordisk's net margin is 26.7% versus 16.3% for AstraZeneca.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Novo Nordisk, AstraZeneca.| Metric | Novo Nordisk | AstraZeneca |
|---|---|---|
| Market Cap | - | - |
| Revenue | $12.09B | $15.38B |
| Cost of Revenue | $2.63B | $2.52B |
| Gross Profit | $9.45B | $12.86B |
| Operating Income | $4.17B | $3.16B |
| Net Income | $3.23B | $2.51B |
| R&D Expense | $2.74B | $4.05B |
| Earnings Per Share | $0.73 | $1.59 |
| Gross Margin | 78.2% | 83.6% |
| Operating Margin | 34.5% | 20.6% |
| Net Profit Margin | 26.7% | 16.3% |
| Free Cash Flow | $6.53B | $2.13B |
| Cumulative Free Cash Flow | $107.39B | $121.22B |
| Operating Cash Flow | $8.50B | $2.89B |
| Cash & Equivalents | $6.85B | $4.89B |